Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Hematologic Diseases 1Head and Neck Neoplasms 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Blast Crisis 1

Interventions

fludarabine 4fludarabine phosphate 3asciminib 3venetoclax 2gilteritinib 2Whole-Body Irradiation 2Tacrolimus 2Idarubicin 2Cytarabine 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2ponatinib 1nilotinib 1enasidenib 1blinatumomab 1aldesleukin 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Methotrexate 1Mesna 1Melphalan 1Interleukin-2 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × Imatinib Mesylate × 90 days × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡